Invesco S&P Smallcap 600 GARP ETF(GRPZ.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Invesco S&P Smallcap 600 GARP ETF
GRPZ.US
News
View More

TransMedics Group Inc. Unveils Presentation on Revolutionizing Organ Transplantation with OCS Platform

TransMedics Group Inc. has unveiled a presentation on its innovative Organ Care System (OCS) platform, which addresses the limitations of traditional cold storage for donor organs. The OCS platform aims to reduce ischemic damage and enhance organ viability through continuous clinical assessment and integrated biosensors. The presentation highlights substantial clinical evidence supporting the platform's effectiveness for both DBD and DCD organs. The full presentation is accessible via a provided link.

Reuters·
US
TMDX
-0.22%
Reuters·
US
TMDX
-0.22%

Krystal Biotech Projects 2026 R&D and SG&A Expenses Between $175 Million and $195 Million

Krystal Biotech Inc. projects its 2026 combined non-GAAP R&D and SG&A expenses to be between $175 million and $195 million, excluding stock-based compensation. The company anticipates fourth quarter 2025 VYJUVEK® net product revenue of $106 million to $107 million, following a successful launch in Europe and Japan. With a strong clinical pipeline and balance sheet, Krystal is positioned for growth and potential blockbuster launches in the coming years.

Reuters·
US
KRYS
+1.07%
Reuters·
US
KRYS
+1.07%

TransMedics Announces New Global Headquarters and Expansion at Assembly Innovation Park in Somerville, Massachusetts | TMDX Stock News

TransMedics Group, Inc. has announced the signing of a long-term lease for its new global headquarters at Assembly Innovation Park in Somerville, Massachusetts, along with the acquisition of adjacent land. This expansion aims to enhance the company's operational capabilities and attract top talent. The Massachusetts government is supporting this move with a performance-based incentive package, potentially worth up to $18 million, tied to the creation of 600 new jobs. The new headquarters is expected to be operational by January 2028, further solidifying Massachusetts' position in life sciences innovation.

StockTitan·
US
TMDX
-0.22%
StockTitan·
US
TMDX
-0.22%

Krystal Biotech (NASDAQ:KRYS) Price Target Raised to $306.00 at TD Cowen

TD Cowen raised its price target for Krystal Biotech (NASDAQ:KRYS) from $202.00 to $306.00, maintaining a "buy" rating. This suggests a potential upside of 17.52% from the previous close. Other analysts have also upgraded their ratings, with Zacks Research moving from "hold" to "strong-buy" and HC Wainwright setting a target of $310.00. The stock traded at $260.38, with a market cap of $7.55 billion and a P/E ratio of 39.04. Krystal Biotech reported strong earnings, exceeding estimates with $2.66 EPS and $97.80 million in revenue.

Market Beat·
US
KRYS
+1.07%
Market Beat·
US
KRYS
+1.07%

Krystal Biotech Touts Positive KB407 CF Gene Therapy Data, Eyes Repeat Dosing and Registrational Path

Krystal Biotech (NASDAQ:KRYS) announced positive interim results for its inhaled cystic fibrosis gene therapy candidate KB407, confirming wild-type CFTR protein expression in patients' lungs. The company plans to initiate repeat dosing and potentially move towards a registrational study. CEO Krish Krishnan highlighted the breakthrough in CFTR delivery, while Dr. Jorge Lascano noted that some patients do not benefit from existing CFTR modulators. The Phase 1 CORAL-1 study is evaluating the safety and efficacy of KB407, with promising results in patient biopsies showing CFTR expression.

Market Beat·
US
KRYS
+1.07%
Market Beat·
US
KRYS
+1.07%
© 2026 Longbridge｜Disclaimer